AU2004243886A1 - Imageable animal model of SARS infection - Google Patents
Imageable animal model of SARS infection Download PDFInfo
- Publication number
- AU2004243886A1 AU2004243886A1 AU2004243886A AU2004243886A AU2004243886A1 AU 2004243886 A1 AU2004243886 A1 AU 2004243886A1 AU 2004243886 A AU2004243886 A AU 2004243886A AU 2004243886 A AU2004243886 A AU 2004243886A AU 2004243886 A1 AU2004243886 A1 AU 2004243886A1
- Authority
- AU
- Australia
- Prior art keywords
- protein
- group
- coronavirus
- animal model
- test group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000015181 infectious disease Diseases 0.000 title claims description 18
- 238000010171 animal model Methods 0.000 title claims description 12
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 title description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 239000005090 green fluorescent protein Substances 0.000 claims description 32
- 241000711573 Coronaviridae Species 0.000 claims description 31
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 31
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 31
- 102000034287 fluorescent proteins Human genes 0.000 claims description 25
- 108091006047 fluorescent proteins Proteins 0.000 claims description 25
- 241001465754 Metazoa Species 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 11
- 101710172711 Structural protein Proteins 0.000 claims description 8
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 108010028403 hemagglutinin esterase Proteins 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 230000009261 transgenic effect Effects 0.000 claims description 4
- 229960004854 viral vaccine Drugs 0.000 claims description 4
- 101710147732 Small envelope protein Proteins 0.000 claims description 3
- 101710114810 Glycoprotein Proteins 0.000 claims description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 claims description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 claims description 2
- 108010089430 Phosphoproteins Proteins 0.000 claims description 2
- 102000007982 Phosphoproteins Human genes 0.000 claims description 2
- 101710167605 Spike glycoprotein Proteins 0.000 claims description 2
- 108700010904 coronavirus proteins Proteins 0.000 claims 8
- 229940000406 drug candidate Drugs 0.000 claims 2
- 108060003393 Granulin Proteins 0.000 claims 1
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 26
- 108010054624 red fluorescent protein Proteins 0.000 description 24
- 241000711466 Murine hepatitis virus Species 0.000 description 22
- 241000700605 Viruses Species 0.000 description 19
- 238000003384 imaging method Methods 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 230000005284 excitation Effects 0.000 description 10
- 230000010076 replication Effects 0.000 description 9
- 239000003086 colorant Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108091027544 Subgenomic mRNA Proteins 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 238000000799 fluorescence microscopy Methods 0.000 description 5
- 239000012678 infectious agent Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 230000029812 viral genome replication Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000001524 infective effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000017613 viral reproduction Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000242743 Renilla reniformis Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000243290 Aequorea Species 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101001075376 Bos taurus Gamma-glutamyl hydrolase Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108091080980 Hepatitis delta virus ribozyme Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100151951 Homo sapiens SARS1 gene Proteins 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 102100029137 L-xylulose reductase Human genes 0.000 description 1
- 108010080643 L-xylulose reductase Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000008906 Murine coronavirus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000242739 Renilla Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 101150010882 S gene Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010067674 Viral Nonstructural Proteins Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000011846 endoscopic investigation Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000006394 virus-host interaction Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47369103P | 2003-05-27 | 2003-05-27 | |
| US60/473,691 | 2003-05-27 | ||
| PCT/US2004/016976 WO2004106497A2 (en) | 2003-05-27 | 2004-05-27 | Imageable animal model of sars infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004243886A1 true AU2004243886A1 (en) | 2004-12-09 |
Family
ID=33490633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004243886A Abandoned AU2004243886A1 (en) | 2003-05-27 | 2004-05-27 | Imageable animal model of SARS infection |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050039220A1 (https=) |
| EP (1) | EP1628996A4 (https=) |
| JP (1) | JP2007505163A (https=) |
| CN (1) | CN1829732A (https=) |
| AU (1) | AU2004243886A1 (https=) |
| CA (1) | CA2527296A1 (https=) |
| WO (1) | WO2004106497A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102669017B (zh) * | 2011-12-19 | 2015-02-25 | 河南科技大学 | 一种体内细菌生物被膜感染动物模型的构建方法 |
| WO2021147025A1 (en) * | 2020-01-22 | 2021-07-29 | The University Of Hong Kong-Shenzhen Hospital | Anti 2019-ncov vaccine |
| CN114360646A (zh) * | 2020-04-03 | 2022-04-15 | 郑鑫 | 类似sars冠状病毒溯源和评估致病力的方法及装置 |
| WO2021219121A1 (zh) * | 2020-04-30 | 2021-11-04 | 养生堂有限公司 | 用于筛选冠状病毒感染阻断剂的检测试剂及检测方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251384B1 (en) * | 1997-04-28 | 2001-06-26 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
| US6232523B1 (en) * | 1997-04-28 | 2001-05-15 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
| AU749338B2 (en) * | 1997-04-28 | 2002-06-27 | Anticancer, Inc. | Metastasis models using green fluorescent protein (GFP) as a marker |
| CA2403090C (en) * | 2000-03-17 | 2014-06-10 | Anticancer, Inc. | Whole-body optical imaging of gene expression and uses thereof |
| EP1470218B1 (en) * | 2001-05-17 | 2010-07-07 | Universiteit Utrecht | Corona-virus-like particles comprising functionally deleted genomes |
| CA2452876A1 (en) * | 2001-07-09 | 2003-01-23 | Anticancer, Inc. | Imaging infection using fluorescent protein as a marker |
-
2004
- 2004-05-27 WO PCT/US2004/016976 patent/WO2004106497A2/en not_active Ceased
- 2004-05-27 CN CNA2004800218114A patent/CN1829732A/zh active Pending
- 2004-05-27 US US10/856,529 patent/US20050039220A1/en not_active Abandoned
- 2004-05-27 CA CA002527296A patent/CA2527296A1/en not_active Abandoned
- 2004-05-27 EP EP04753740A patent/EP1628996A4/en not_active Withdrawn
- 2004-05-27 JP JP2006533504A patent/JP2007505163A/ja active Pending
- 2004-05-27 AU AU2004243886A patent/AU2004243886A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007505163A (ja) | 2007-03-08 |
| US20050039220A1 (en) | 2005-02-17 |
| WO2004106497A3 (en) | 2005-05-12 |
| CA2527296A1 (en) | 2004-12-09 |
| EP1628996A4 (en) | 2008-01-09 |
| EP1628996A2 (en) | 2006-03-01 |
| CN1829732A (zh) | 2006-09-06 |
| WO2004106497A2 (en) | 2004-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1820020B (zh) | Sars-冠状病毒病毒样颗粒以及应用方法 | |
| JP5054384B2 (ja) | Ｓａｒｓ関連コロナウイルスの新規系統及びその利用 | |
| JP3810791B2 (ja) | 緑色蛍光タンパク質の使用 | |
| CA2523875A1 (en) | Sars virus nucleotide and amino acid sequences and uses thereof | |
| WO2004085650A1 (en) | A high-troughput diagnostic assay for the human virus causing severe acute respiratory syndrome (sars) | |
| Olson et al. | Development of a Sindbis virus expression system that efficiently expresses green fluorescent protein in midguts of Aedes aegypti following per os infection | |
| JPWO2012099279A1 (ja) | 酸化ストレスインジケーター発現用核酸構築物とその使用 | |
| Doszpoly et al. | Full genome sequence of a novel circo-like virus detected in an adult European eel Anguilla anguilla showing signs of cauliflower disease | |
| TW200530271A (en) | Receptor binding polypeptides | |
| US20050039220A1 (en) | Imageable animal model of SARS infection | |
| CN113817753A (zh) | 表达SARS-CoV-2纤突蛋白或其变异体SΔ21的假型化VSV病毒构建和应用 | |
| CN100588708C (zh) | 抗sars疫苗 | |
| KR20060123291A (ko) | 신규한 비정형 폐렴-원인성 바이러스 | |
| Teninges et al. | Rhabdovirus sigma, the hereditary CO2 sensitivity agent of Drosophila: nucleotide sequence of a cDNA clone encoding the glycoprotein | |
| Chinchar et al. | Molecular diagnosis of iridovirus infections in cold-blooded animals | |
| CN100365132C (zh) | 严重急性呼吸综合征流行病学检测的分子标记和方法 | |
| CN115552004A (zh) | 用于治疗ssRNA病毒感染的诱饵转录物 | |
| CN100360557C (zh) | Sars病毒s蛋白及其疫苗和用其筛选药物的方法 | |
| Li et al. | An induced hypersensitive-like response limits expression of foreign peptides via a recombinant TMV-based vector in a susceptible tobacco | |
| CN100429321C (zh) | Sars冠状病毒orf8区域的应用 | |
| CN100413537C (zh) | Sars冠状病毒全病毒疫苗 | |
| CN1454996A (zh) | 筛选抗SARS冠状病毒药物用非感染性病毒重组基因SARS－CoV－EGFP | |
| Gallo et al. | Components in Human Leukemia | |
| KR20100121289A (ko) | 유전자재조합 돼지열병 백신바이러스 Ｆｌｃ―ＬＯＭ ｖｉｒｕｓ 및 이의 제조방법 | |
| Thiel et al. | Genome Organization and Reverse Genetic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |